WO1998055593A1 - Attachment of unmodified nucleic acids to silanized solid phase surfaces - Google Patents
Attachment of unmodified nucleic acids to silanized solid phase surfaces Download PDFInfo
- Publication number
- WO1998055593A1 WO1998055593A1 PCT/US1998/011662 US9811662W WO9855593A1 WO 1998055593 A1 WO1998055593 A1 WO 1998055593A1 US 9811662 W US9811662 W US 9811662W WO 9855593 A1 WO9855593 A1 WO 9855593A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- silane
- oligonucleotides
- attachment
- solid phase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
- C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Definitions
- the invention relates to a simple, and preferably cost effective, method for immobilizing nucleic acid molecules onto a solid support
- the invention further concerns the use of such immobilized molecules in nucleic acid hybridization assays, sequencing by hybridization assays, and genetic analyses and combinatorial analyses involving nucleic acids or proteins for screening applications
- nucleic acid molecules The analysis of the structure, organization and sequence of nucleic acid molecules is of profound importance in the prediction, diagnosis and treatment of human and animal disease, in forensics, in epidemiology and public health, and in the elucidation of the factors that control gene expression and development Methods for immobilizing nucleic acids are often important in these types of analyses Three areas of particular importance involve hybridization assays, nucleic acid sequencing, and the analysis of genomic polymorphisms
- nucleic acid "probe” molecule to hybridize (i e base pair) to a complementary nucleic acid "target” molecule forms the cornerstone for a wide array of diagnostic and therapeutic procedures
- Hybridization assays are extensively used in molecular biology and medicine Methods of performing such hybridization reactions are disclosed by, for example, Sambrook, J. et al. (In. Molecular Cloning. A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989)), Haymes, B.D , et al. (In Nucleic acid
- VNTRs variable nucleotide type polymorphisms
- single nucleotide polymorphisms constitute sites of variation flanked by regions of invariant sequence, their analysis requires no more than the determination of the identity of the single nucleotide present at the site of variation, it is unnecessary to determine a complete gene sequence for each patient Several methods have been developed to facilitate the analysis of such single nucleotide polymorphisms
- the polymorphic site on the target molecule contains a nucleotide that is complementary to the particular exonuclease-resistant nucleotide derivative present, then that derivative will be incorporated onto the end of the hybridized primer Such incorporation renders the primer resistant to exonuclease, and thereby permits its detection Since the identity of the exonuclease-resistant derivative of the sample is known, a finding that the primer has become resistant to exonucleases reveals that the nucleotide present in the polymorphic site of the target molecule was complementary to that of the nucleotide derivative used in the reaction
- the Mundy method has the advantage that it does not require the determination of large amounts of extraneous sequence data It has the disadvantages of destroying the amplified target sequences, and unmodified primer and of being extremely sensitive to the rate of polymerase incorporation of the specific exonuclease-resistant nucleotide being used
- Cheesman, P (U S Patent No 5,302,509) describes a method for sequencing a single stranded DNA molecule using fluorescently labeled 3 '-blocked nucleotide triphosphates
- An apparatus for the separation, concentration and detection of a DNA molecule in a liquid sample has been recently described by Ritterband, et al. (PCT Patent Application No W095/17676)
- OLA Oligonucleotide Ligation Assay
- the OLA protocol uses two oligonucleotides which are designed to be capable of hybridizing to abutting sequences of a single strand of a target
- One of the oligonucleotides is biotinylated, and the other is detectably labeled If the precise complementary sequence is found in a target molecule, the oligonucleotides will hybridize such that their termini abut, and create a ligation substrate Ligation then permits the labeled oligonucleotide to be recovered using avidin, or another biotin Iigand Nickerson, D A et al have described a nucleic acid detection assay that combines attributes of PCR and OLA (Nickerson, D A et al ,
- Polystyrene is a very hydrophobic material because it normally contains no hydrophilic groups Microtiter plate manufacturers have developed methods of introducing such groups (hydroxyl, carboxylate and others) onto the surface of microwells to increase the hydrophilic nature of the surface Theoretically, this allows macromolecules to bind through a combination of hydrophobic and hydrophilic interactions (Baier et al . Science 162 1360-1368 (1968), Baier et al , J Biomed Mater Res 18 335-355 (1984), Good et al . in L H Lee (ed ) Fundamentals of Adhesion.
- polystyrene may also be used to describe styrene-containing copolymers such as styrene/divinyl benzene, styrene/butadiene, styrene/vinyl benzyl chloride and others
- the present invention provides an improved immobilization method that permits the rapid, and inexpensive immobilization of nucleic acid molecules to a solid phase
- the invention allows immobilization of oligonucleotides by incubation with a silane- containing or silane-treated solid phase
- the immobilized molecules can be used for nucleic acid hybridization assays, sequencing hybridization assays, genetic analyses, combinatorial analyses involving nucleic acids or proteins, and other screening applications such as protein-DNA binding assays
- the invention provides a method for immobilizing a nucleic acid molecule to a solid phase, the method comprising the steps of
- the invention particularly concerns the embodiments of the above method wherein, in step A, the silane is selected from the group consisting of 3-mercapto- propyl-trimethoxysilane and 3-glycidoxy propyl-trimethoxysilane
- the silane is selected from the group consisting of 3-mercapto- propyl-trimethoxysilane and 3-glycidoxy propyl-trimethoxysilane
- the invention further pertains to oligonucleotide coated surfaces useful in genetic analysis and other screening applications such as protein-DNA binding assays
- the invention particularly concerns oligonucleotide arrays comprising epoxy- or mercapto-silane coated surfaces and unmodified oligonucleotides covalently attached to the epoxy or mercapto-silane, such arrays being useful for nucleic acid hybridization assays, sequencing hybridization assays, genetic analyses, combinatorial analyses involving nucleic acids or proteins, and other screening applications such as protein- DNA binding assays
- the features of the coated surface enable standardized patterning of unique oligonucleotides onto silane surface coatings
- the invention further pertains to simultaneous patterning of multiple DNA probes in a high density and in a variety of array formats
- the present invention concerns a method for immobilizing nucleic acid molecules onto a solid-phase
- several methods have been proposed as suitable for immobilizing an oligonucleotide to a solid support Holmstrom, K et al., for example, exploit the affinity of biotin for avidin and streptavidin, and immobilize biotinylated nucleic acid molecules to avidin/streptavidin coated supports (Holmstrom, K et al, Anal Biochem 209 278-283 (1993))
- Another method requires the precoating of the polystyrene or glass solid phases with poly-L-Lys or poly L-Lys, Phe, followed by the covalent attachment of either amino- or sulfhydryl-modified oligonucleotides using bi-functional crosslinking reagents Unlike the present invention, both methods require the use of modified oligonucleotides as well as a pretreatment of the solid phase, however, the present invention discloses a
- unmodified refers to the absence of any requirement for specialized reactive groups It does not refer to the exclusion of nucleotides or oligonucleotides that have such groups, or that are biotinylated, flouresceinated, etc
- Kawai, S. et al describes an alternative method in which short oligonucleotide probes were ligated together to form multimers and these were ligated into a phagemid vector (Kawai, S et al, Anal Biochem 209 63-69 (1993))
- the oligonucleotides were immobilized onto polystyrene plates and fixed by UV irradiation at 254 nm
- a method for the direct covalent attachment of short, 5'-phosphorylated primers to chemically modified polystyrene plates (“Covalink" plates, Nunc) has also been proposed by Rasmussen, S R et al.
- the Stimpson article discloses the immobilization of 3' amino-linked oligonucleotides into an organized array on a glycidoxypropyl silane treated glass slide
- Lamture et al. (Nucleic Acids Res. 22 2121-2125 (1994)) describes the immobilization of 3' amino modified oligonucleotides to a 3-glycidoxypropyl- trimethoxysilane coated silicon wafer in the presence of 0 1M KOH
- the oligonucleotides are covalently immobilized to the solid support by means of a secondary amine linkage Beattie et al. (Clin. Chem.
- the present invention provides several significant improvements over the prior art
- the present invention provides a low-cost, stable method for the covalent attachment of "unmodified” oligonucleotides to a silanized solid-phase wherein the covalently bound oligonucleotides have wide uses in genetic and combinatorial analysis involving nucleic acids or proteins
- Covalent attachment of oligonucleotides onto solid phase surfaces is therefore achieved without modification of oligonucleotides, thereby dramatically reducing the cost and eliminating the variation in quality of modified oligonucleotides
- the silanized surface of the present method provides a very hydrophobic surface which allows oligonucleotide probe droplets to form at specific and localized positions on the solid surface
- multiple probes can be patterned simultaneously on the surface using, for example, a robotic liquid delivery system or an ink-jet printing technique with no cross contamination between probes, even at a high probe density (10,000 probes/cm )
- the process can be easily automated and scaled-up using an off-the-shelf robot or ink-jet printing instrument
- Standard covalent attachment chemistries require the use of photolithographic and laser patterning techniques which require multiple masking and lifting steps for high density DNA array preparation
- the present method does not require the use of expensive crosslinking agents These crosslinking agents are difficult to use because of their sensitivity to air and humidity Therefore, the present method provides a new, efficient and inexpensive method for DNA array preparation, and particularly for large scale DNA array preparation
- this invention describes a method for immobilizing nucleic acids on silane coated solid phase surfaces which is useful in genetic analysis and other screening applications such as protein-DNA binding assays.
- the invention pertains to oligonucleotide arrays comprising silane coated solid phase surfaces and unmodified or modified oligonucleotides covalently attached to the silane coated solid phase, such arrays being useful for genetic analyses and combinatorial analyses involving nucleic acids or proteins
- the features of the coated surface enable standardized patterning of unique oligunucleotides onto silane surface coatings
- the invention provides for methods of covalent attachment of unmodified oligonucleotides onto mercapto-silanized surface or epoxy-silanized surfaces with high density and high stability
- the ease of preparation of unmodified oligonucleotides coupled with stable ether (epoxy) or thio-ether (mercapto) linkage attachments renders this method the most cost effective, with little or no variation in terms of the quality of oligonucleotides, stability of attachment linkage and consistency in large scale batch to batch manufactures
- the hydrophobic property of silane surfaces also allows simultaneous patterning of multiple DNA probes in a high density and in a variety of array formats
- a DNA array that is stable to high salt and denaturing conditions such as DMF, urea and elevated temperatures, has wide uses in miniaturized biotechniques such as genetic testing, sequencing by hybridization and combinatory selection of DNA binding molecules
- the covalent attachment of the present invention can be distinguished from other means of attachment, such as van der Waals interaction and ion-ion interactions
- the covalently immobilized oligonucleotide will not be released from the solid-phase during subsequent wash steps
- the covalent attachment generally provides more stable binding than noncovalent attachment under elevated temperatures and upon other chemical treatment, thus, giving more flexibility for use in biochemical processes
- a selective, highly efficient method employs an epoxy-based attachment chemistry to covalently attach nucleic acid molecules in an end selective manner to a solid-phase
- Oligonucleotides have two free hydroxyl groups at the 5'- and 3'- ends which allow oligonucleotides to undergo chemical and/or enzymatic elongation, ligation and circularization
- the differences in steric hindrances between these two end hydroxyl groups have enabled 5'-selective esterification, 5'-selective tritylation and 5'- selective oxidation in controlled conditions
- Unmodified oligonucleotides for attachment to solid phases under certain controlled conditions thus have the potential for the 5'-OH to react preferentially over the 3'-OH towards epoxy activated surfaces
- End-selective attachment is achieved in epoxy chemistry by taking advantage of differences in steric hindrance between the 5'
- the covalent bond described in the epoxy-based preferred embodiment of the present invention is a covalent ether linkage End selective attachment ensures that the full sequence of the immobilized oligonucleotide is accessible for any desired biochemical reaction. Since there is no need for any modification of oligonucleotides, this embodiment dramatically reduces the cost and variation in terms of the quality of oligonucleotides
- the epoxy-based attachment chemistry allows attachment of all forms of DNA including per products or genomic DNA to the silanized surface Furthermore, in the case of epoxy-based attachment chemistry, the chemical bonds between the silane layer and oligonucleotides are covalent ether linkages, which are stable to heat, high salt, and elevated temperatures
- the present invention describes in another preferred embodiment a random, highly efficient method which employs a mercapto-based attachment chemistry to covalently attach nucleic acid molecules in a non-specific manner to a solid-phase
- the covalent bond described in this second preferred embodiment of the present invention is a covalent thioether linkage Because this embodiment relies on nonspecific binding, the full sequence of the immobilized oligonucleotide may not be accessible for all desired biochemical reactions Since the mercapto group is very reactive in terms of radical reactions and easily deionized under lower pH (pH 9), this allows a variety of reactions to occur with nucleic acids Heterocyclic purines (electron rich system stabilizing radicals, particularly at position 7 of purines) and pyrimidines (electron deficient, a nucleophile acceptor) in oligonucleotides are good acceptors for either nucleophilic attack or radical reactions In mercapto chemistry the highly reactive mercapto groups allow mild conditions for attachment The resulting array can undergo a variety of biochemical reactions and allows hybridization with high efficiency The mercapto-based attachment chemistry allows attachment of all forms of DNA including per products or genomic DNA to the silanized surface Furthermore, in the case of mercap
- the unmodified nucleic acid molecules may be either genomic DNA (i e , DNA containing a non-translated region), cDNA (i e ,
- the nucleic acid molecule may also be either single or double stranded While any unmodified nucleic acid molecule may be immobilized using the present invention, the preferred nucleic acid molecule of the present invention is an unmodified single-stranded synthetic oligonucleotide The method for making a synthetic oligonucleotide has been previously described by Gait,
- Synthesis of unmodified oligonucleotides of about 10 to about 250 nucleotides in length may be performed on an ABI 392 DNA/RNA synthesizer according to phosphoramidite chemistry
- the unmodified oligonucleotides can be purified (for example, using an HPLC column) to separate the full-length oligonucleotides from any contaminating prematurely terminated (i e , shortened) oligonucleotides Prior to use in the coupling reaction, the oligonucleotides are concentrated, and, if desired, the molar concentration of the oligonucleotides can be determined
- glass is the preferred support
- the support can be fashioned as a bead, dipstick, test tube, pin column, etc
- an especially preferred support is a glass slide
- the solid support can be a form of polystyrene plastic (e g , 96-well microtiter plate, etc )
- mercaptosilane compounds such as 3-mercapto- propyltrimethoxy-silane, 3 -mercaptopropyltriethoxysilane, (mercapto-methyl) dimethoxysilane and (mercaptoethyl)ethyldimethoxysilane, etc can be used in the present invention for coating the solid support with sulfhydryl groups
- the general formula for a mercaptosilane that can be used in this invention is
- X is a hydrolyzable group such as alkoxy, acyloxy, amine or halide, etc
- X is a hydrolyzable group such as alkoxy, acyloxy, amine or halide, etc
- All of the mercaptosilanes mentioned above are commercially available from United Chemical,
- the silane can be coated onto the solid-phase by any of a number of means
- the mercaptosilane can be deposited onto the solid surface as an aerosol or a vapor
- the silane can be spread onto the solid-surface by mechanical means (e g , a spreader bar, a saturated cloth, etc )
- An important feature of the present invention is the hydrophobic nature of silanes Because of this feature, it is possible for an aqueous solution to form extremely well defined beads on the surface of any solid support coated with mercaptosilane With an automated delivery system, such as a Hamilton robot or ink-jet printing method, it is possible to form a very complex array of oligonucleotide probes on a mercaptosilane coated glass slide Such methods can deliver nano to pico-liter size droplets with sub-millimeter spacing Because the aqueous beads are extremely well defined, it is possible to create an array with an extremely high density of oligonucleotide probes Thus, it is possible to create arrays having greater than about 10,000 probe droplets/cm 2
- Immobilized nucleic acid molecules and more preferably, immobilized oligonucleotides, make an ideal diagnostic tool Specifically, their versatility and simplicity make them ideal diagnostic tools for the detection of infectious and genetic diseases, mutation analysis, etc
- nucleic acid molecules are immobilized to the solid support
- one of the preferred embodiments of the invention is to arrange the nucleic acid molecules into an ordered array
- an array is an orderly arrangement of nucleic acid molecules, as in a matrix of rows and columns
- the chemistry of the present invention is such that an individual array can contain either a finite or an infinite number of unique immobilized nucleic acid molecules
- two preferred methods to make a nucleic acid array one is to synthesize the specific oligonucleotide sequences directly onto the solid-phase in the desired pattern (Southern, et al, Nucl Acids Res 22 1368-1373 (1994), Maskos, et al, Nucl Acids Res 20 1679-1684 (1992), and Pease, et_al, Proc Natl Aced Sci 91 5022-5026 (1994), all of which are herein incorporated by reference) and the other is to pre-synthesize the oligonucleotides on
- the efficiency of the coupling step of each base will affect the quality and integrity of the nucleic acid molecule array
- This method generally yields a large percentage of undesired incoinplete (shortened) sequences which can create problems in the analysis step and effect the integrity of the analysis
- the quality and integrity of an array synthesized according to the first method is inversely proportional to the length of the nucleic acid molecule Specifically, the synthesis of longer oligonucleotides results in a higher percentage of incomplete, shortened sequences
- a second, more preferred, method for nucleic acid array synthesis utilizes an automated DNA synthesizer for DNA synthesis
- the controlled chemistry of an automated DNA synthesizer allows for the synthesis of longer, higher quality DNA molecules than is possible with the first method
- the nucleic acid molecules synthesized according to the second method can be purified prior to the coupling step Therefore, the quality of the nucleic acid molecule array can be expected to be much higher than the quality of the nucleic acid array of the first method
- a simple, effective and specific oligonucleotide coupling chemistry is lacking for the attachment of presynthesized oligonucleotides
- the present invention describes a simple, effective and efficient method for coupling a pre-synthesized unmodified oligonucleotide onto a solid-phase by means of either an ether or thioether covalent linkage
- covalently immobilized nucleic acid molecules may be used to detect specific PCR products by hybridization where the capture probe is immobilized on the solid phase (Ranki et al, Gene 21 77-85 (1983), Keller et al, J
- a preferred method would be to prepare a single-stranded PCR product before hybridization A sample, suspected to contain the target molecule, or an amplification product thereof, would then be exposed to the solid-surface and permitted to hybridize to the bound oligonucleotide
- the methods of the present invention do not require that the target nucleic acid contain only one of its natural two strands
- the methods of the present invention may be practiced on either double-stranded DNA, or on single-stranded DNA obtained by, for example, alkali treatment of native DNA The presence of the unused (non- template) strand does not affect the reaction
- Single- stranded DNA molecules may be produced using the single-stranded DNA bacteriophage M13 (Messing, J et al , Meth Enzymol 101 20 (1983), see also, Sambrook, J , et al (In Molecular Cloning A Laboratory Manual.
- nuclease resistant nucleotide derivatives employ nuclease resistant nucleotide derivatives, and incorporate such derivatives, by chemical synthesis or enzymatic means, into primer molecules, or their extension products, in place of naturally occurring nucleotides
- Suitable nucleotide derivatives include derivatives in which one or two of the non-bridging oxygen molecules of the phosphate moiety of a nucleotide has been replaced with a sulfur-containing group (especially a phosphorothioate), an alkyl group
- Phosphorothioate deoxyribonucleotide or ribo-nucleotide derivatives are the most preferred nucleotide derivatives Methods of producing and using such phosphorothioate derivatives are disclosed by Nikiforov, T (U S Patent No 5,518,900)
- the methods of the present invention may also be used in the practice of solid- phase sequencing as described by Khrapko, K R et al. (DNA Seq , 1 375-388 (1991 ) and Drmanac, R and Crkvenjakov, R , Int J Genome Res . 1 1-1 1 (1992)), both herein are incorporated by reference
- the methods of the present invention may also be used to immobilize the oligonucleotides that are used in the GBATM Genetic Bit Analysis (Goelet, P et al , PCT Application No 92/15712), herein incorporated by reference GBATM Genetic Bit Analysis a solid-phase method for the typing of single-nucleotide polymorphisms
- Oligonucleotides having a defined sequence complementary to a region that lies immediately proximal or distal to the variable nucleotide of a polymorphism would thus be provided to a polystyrene microtiter well or glass plate, and incubated with a salt, in accordance with the above-described methods The immobilized primer is then incubated in the presence of a DNA molecule
- such incubation occurs in the complete absence of any dNTP (i e dATP, dCTP, dGTP, or dTTP), but only in the presence of one or more chain terminating nucleotide derivatives (such as a dideoxynucleotide derivative), and under conditions sufficient to permit the incorporation of such a derivative onto the 3'-terminus of the primer
- dNTP i e dATP, dCTP, dGTP, or dTTP
- chain terminating nucleotide derivatives such as a dideoxynucleotide derivative
- oligonucleotide primers can be immobilized on solid phases like polystyrene or glass, hybridized to PCR-derived, single-stranded templates, and subjected to enzymatic extension at their
- the nature of the incorporated ddNTP is determined by the nucleotide that is located in the opposite strand (the polymorphic nucleotide) This assay can be conveniently carried out both in polystyrene ELISA plates, or on glass slides.
- the nucleotide of the polymorphic site is thus determined by assaying which of the set of labeled nucleotides has been incorporated onto the 3'- terminus of the bound oligonucleotide by a primer-dependent polymerase Most preferably, where multiple dideoxynucleotide derivatives are simultaneously employed, different labels will be used to permit the differential determination of the identity of the incorporated dideoxynucleotide derivative
- ligase-mediated GBATM genetic bit analysis is a more specific version of the GBATM genetic bit analysis assay The additional specificity arises from the addition of a second hybridization step and a ligation step
- the first oligonucleotide is a primer that is complementary to the immediately 3'-distal invariant sequence of the polymorphism
- the 3'-end of the oligonucleotide is attached to the plate
- a second linker oligonucleotide is complementary to the 5'-proximal sequence of the polymorphism being analyzed, but is incapable of hybridizing to the first oligonucleotide
- the second linker oligonucleotide is phosphorylated at both its 3' and 5' ends
- These oligonucleotides are incubated in the presence of DNA containing the single nucleotide polymorphism that is to be analyzed, and at least one 2'- deoxynucleotide 5'-triphosphate
- the incubation reaction further includes a DNA polymerase and a DNA ligase
- the tethered and soluble oligonucleotides are thus capable of hybridizing to the same
- Table 1 shows the end selective attachment of un-modified oligonucleotides by epoxy-based chemistry Attachment was performed on an epoxy silanized slide with various concentrations of oligonucleotides in 12 5 mM NaOH for overnight and washed sequentially with TNTw and 50 mM NaOH
- 5 '-att refers to the attachment reading of 3'-phosphorylated oligonucleotides
- 3 '-att refers to the attachment reading of 5'-phosphorylated oligonucleotides
- Middle att refers to the heterocyclic amino attachment reading of both 3'- and 5 '-end blocked oligonucleotides
- the 32 P isotopes images were analyzed on phosphor image quanta software Attachment at a concentration of 10 uM gave the best selectivity ratio of 87 1 of 5'-end vs 3'-end attachment Attachment at concentration of 5 uM gave the best end selectivity ratio of 19 1 of 3 '-plus 5'-
- Attachment was obtained by a two-step process of silane treatment and oligonucleotide binding Glass slides were etched in 25% aqueous ammonium hydroxide, rinsed in milliQ water, then in 95% ethanol They were treated for about 30 minutes in 3-mercapto-propyl-trimethoxysilane (MPTS) Slides were cured for at least 24 hours under dry inert gas (Ar or N 2 ) 2 5-10 uM cone of oligonucleotides in an alkaline solution were applied onto cured slides in any desired array formats, in a covered chamber for an overnight, after which they were stored in water or a covered chamber for later use A functional test with hybridization and enzymatic reactions gave the desired signal (Figure 2)
- Figure 2 shows the results of mercapto-based attachment chemistry and functional assay by hybridization and GBA The data was based on phosphor imaging quanta analysis
- the X axis represents the input concentration of oligonucleotides used for attachment from 0 3
- a GBA primer having a poly-T-o residue long spacer arm is attached to the glass surface by means of the previously described epoxy-based chemistry or mercapto- based chemistry Standard GBA biochemistry is used to analyze two synthetic templates Each synthetic template is hybridized to GBA primer immobilized to the treated glass slide and treated with an extension mix containing all of the extension reaction components, exonuclease-free Klenow fragment of the 10 coll polymerase and each of four fluorescein-labeled ddNTP's and co-ddNTP's or j2 P-ddATP The signal was recorded by enzyme-mediated fluorescence using a Cytoflour II fluorescent plate reader (Figure 1) or phosphor image quanta analysis Figure 1 shows the results of GBA functional assay of epoxy-based attachment chemistry The 27-mer primer with (T)10 spacer arm at 5' was used for attachment (SEQ ID No 1 ) Standard GBA conditions were used in terms of nucleoside triphosphate concentration and enzyme concentration and reaction conditions Synthetic template 1 5'
- Genomic DNA was isolated using the SDS/Proteinase K procedure (Maniatis, T Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor (1989)) from peripheral blood nucleated cells of humans or horses enriched from red blood cells by selective lysis accomplished by diluting blood with a three fold volume excess of ACK lysing buffer (0 15 M ammonium chloride, 1 mM potassium bicarbonate, 0.1 mM EDTA) Oligonucleotides were prepared by solid-phase phosphoramidite chemistry using an Applied Biosystems, Inc.
- Table 3 depicts the results of an experiment employing a synthetic template 1 5' ACA CTC TAA GAT TTT CTG CAT AGC ATT ATT (SEQ ID No 2)(designed to give a GBA signal in base A) and a synthetic template 2, 5' GGA CAC TAA GAT TTT CGT CAT AGC ATT AAT (SEQ ID No 3)(designed to give a signal in base T)
- the primer used was (T) 10 TCA TTA ATG CTA TGC AGA AAA TCT TAG (SEQ ID No 1) Both signals give strong signals in the expected bases with virtually no noise observed in the other bases (the Signal to Noise Ratio ranged from 520 1 to 600 1)
- Another method for the automated delivery of the oligonucleotide solution employs an ink-jet printing technique performed by MicroFab (MicroFab Technologies, Inc , Piano, Texas) In one experiment, four different spot spacings (center to center) and eight different droplet sizes are tested on the mercaptosilane coated surface using an oligonucleotide labeled at the 3 '-terminus with fluorescein
- the format of the slides, depicted in Table 4 are as follows'
- the labeled oligonucleotides are detected using a Molecular Dynamic Fluorlmager 595
- the ink-jet printing technique is a suitable method for the manufacture of oligonucleotide arrays with sub-millimeter spacing and nano to pico-liter droplet sizes As such, the ink-jet printing technique is suitable for large scale manufacture of oligo arrays
- a Hamilton 2200 automated pipeting robot is used to make arrays of oligonucleotide drops, ranging in size from about 100 nl to about 250 nl, with 1 mm spacing between dots
- the small volumes of oligonucleotide solution used with the automated pipeting robot allows for rapid drying of the oligonucleotide drops
- a Hamilton robot can be programmed to deliver nano to pico-liter size droplets with sub-millimeter spacing
- ADDRESSEE Howrey & Simon
- B STREET: 1299 Pennsylvania Avenue, N.W.
- TELECOMMUNICATION INFORMATION (A) TELEPHONE: 202 383-6857 (B) TELEFAX: 202 383-6610
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98925267A EP0996705A4 (en) | 1997-06-06 | 1998-06-05 | Attachment of unmodified nucleic acids to silanized solid phase surfaces |
JP50294099A JP2002506347A (en) | 1997-06-06 | 1998-06-05 | Attachment of unmodified nucleic acid to silanized solid phase surface |
CA002292896A CA2292896A1 (en) | 1997-06-06 | 1998-06-05 | Attachment of unmodified nucleic acids to silanized solid phase surfaces |
AU77260/98A AU739412B2 (en) | 1997-06-06 | 1998-06-05 | Attachment of unmodified nucleic acids to silanized solid phase surfaces |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/870,010 US5919626A (en) | 1997-06-06 | 1997-06-06 | Attachment of unmodified nucleic acids to silanized solid phase surfaces |
US08/870,010 | 1997-06-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998055593A1 true WO1998055593A1 (en) | 1998-12-10 |
Family
ID=25354612
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/011662 WO1998055593A1 (en) | 1997-06-06 | 1998-06-05 | Attachment of unmodified nucleic acids to silanized solid phase surfaces |
Country Status (6)
Country | Link |
---|---|
US (3) | US5919626A (en) |
EP (1) | EP0996705A4 (en) |
JP (1) | JP2002506347A (en) |
AU (1) | AU739412B2 (en) |
CA (1) | CA2292896A1 (en) |
WO (1) | WO1998055593A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1104687A2 (en) * | 1999-11-29 | 2001-06-06 | Nisshinbo Industries, Inc. | Nucleic acid-immobilized substrate |
WO2001062378A2 (en) * | 2000-02-22 | 2001-08-30 | Genospectra, Inc. | Microarray fabrication techniques and apparatus |
WO2001062377A2 (en) * | 2000-02-22 | 2001-08-30 | Genospectra, Inc. | Microarray fabrication techniques and apparatus |
DE10029914A1 (en) * | 2000-06-19 | 2002-01-03 | Epigenomics Ag | Method for the highly parallel analysis of polymorphisms |
EP1223149A1 (en) * | 2001-01-10 | 2002-07-17 | Corning Incorporated | Silsesquioxane-coated substrates for immobilizing biomolecules |
JP2005519634A (en) * | 2001-10-12 | 2005-07-07 | スペクトラル ジェノミクス、インク. | Nucleic acid compositions and arrays and methods using them |
US7501245B2 (en) | 1999-06-28 | 2009-03-10 | Helicos Biosciences Corp. | Methods and apparatuses for analyzing polynucleotide sequences |
US7645596B2 (en) | 1998-05-01 | 2010-01-12 | Arizona Board Of Regents | Method of determining the nucleotide sequence of oligonucleotides and DNA molecules |
US7666593B2 (en) | 2005-08-26 | 2010-02-23 | Helicos Biosciences Corporation | Single molecule sequencing of captured nucleic acids |
US7981604B2 (en) | 2004-02-19 | 2011-07-19 | California Institute Of Technology | Methods and kits for analyzing polynucleotide sequences |
US9012144B2 (en) | 2003-11-12 | 2015-04-21 | Fluidigm Corporation | Short cycle methods for sequencing polynucleotides |
US9096898B2 (en) | 1998-05-01 | 2015-08-04 | Life Technologies Corporation | Method of determining the nucleotide sequence of oligonucleotides and DNA molecules |
Families Citing this family (218)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE504798C2 (en) * | 1995-06-16 | 1997-04-28 | Ulf Landegren | Immunoassay and test kits with two reagents that can be cross-linked if adsorbed to the analyte |
GB9714716D0 (en) * | 1997-07-11 | 1997-09-17 | Brax Genomics Ltd | Characterising nucleic acids |
US6391655B1 (en) * | 1997-07-30 | 2002-05-21 | Corning Incorporated | Oxidized styrenic polymers for DNA binding |
US6762019B2 (en) * | 1997-09-30 | 2004-07-13 | Surmodics, Inc. | Epoxide polymer surfaces |
US6465178B2 (en) * | 1997-09-30 | 2002-10-15 | Surmodics, Inc. | Target molecule attachment to surfaces |
US6979728B2 (en) * | 1998-05-04 | 2005-12-27 | Baylor College Of Medicine | Articles of manufacture and methods for array based analysis of biological molecules |
WO1999067414A1 (en) * | 1998-06-24 | 1999-12-29 | Glaxo Group Limited | Nucleotide detection method |
US20100130368A1 (en) * | 1998-07-30 | 2010-05-27 | Shankar Balasubramanian | Method and system for sequencing polynucleotides |
US20040106110A1 (en) * | 1998-07-30 | 2004-06-03 | Solexa, Ltd. | Preparation of polynucleotide arrays |
US6703228B1 (en) | 1998-09-25 | 2004-03-09 | Massachusetts Institute Of Technology | Methods and products related to genotyping and DNA analysis |
EP1001037A3 (en) * | 1998-09-28 | 2003-10-01 | Whitehead Institute For Biomedical Research | Pre-selection and isolation of single nucleotide polymorphisms |
US6232068B1 (en) * | 1999-01-22 | 2001-05-15 | Rosetta Inpharmatics, Inc. | Monitoring of gene expression by detecting hybridization to nucleic acid arrays using anti-heteronucleic acid antibodies |
DE60000836T2 (en) * | 1999-02-08 | 2003-09-04 | Fuji Photo Film Co Ltd | METHOD FOR PRODUCING A DNA CHIP |
US20010051349A1 (en) | 2000-02-17 | 2001-12-13 | Glycominds Ltd. | Combinatorial complex carbohydrate libraries and methods for the manufacture and uses thereof |
EP1159453B1 (en) | 1999-03-10 | 2008-05-28 | ASM Scientific, Inc. | A method for direct nucleic acid sequencing |
US7011940B1 (en) * | 1999-04-14 | 2006-03-14 | Medical Discovery Partners Llc | Quality control for cytochemical assays |
US7932213B2 (en) * | 1999-05-11 | 2011-04-26 | President And Fellows Of Harvard College | Small molecule printing |
US6824987B1 (en) | 1999-05-11 | 2004-11-30 | President And Fellows Of Harvard College | Small molecule printing |
ATE490777T1 (en) | 1999-06-01 | 2010-12-15 | Baylor College Medicine | COMPOSITIONS AND METHODS FOR THE THERAPEUTIC USE OF A SEQUENCE ASSOCIATED WITH THE GENE ATONAL |
AU5785400A (en) | 1999-07-02 | 2001-01-22 | Symyx Technologies, Inc. | Polymer brushes for immobilizing molecules to a surface or substrate, where the polymers have water-soluble or water-dispersible segments and probes bonded thereto |
US6383783B1 (en) | 1999-09-21 | 2002-05-07 | 3M Innovative Properties Company | Nucleic acid isolation by adhering to hydrophobic solid phase and removing with nonionic surfactant |
US6376177B1 (en) | 1999-10-06 | 2002-04-23 | Virtual Pro, Inc. | Apparatus and method for the analysis of nucleic acids hybridization on high density NA chips |
WO2001027327A2 (en) | 1999-10-08 | 2001-04-19 | Protogene Laboratories, Inc. | Method and apparatus for performing large numbers of reactions using array assembly |
US7109024B2 (en) * | 1999-11-15 | 2006-09-19 | Dr. Chip Biotechnology Inc. | Biomolecule-bound substrates |
EP1130121A3 (en) * | 2000-01-26 | 2003-04-16 | Nisshinbo Industries Inc. | Immobilized nucleic acid and method for detecting nucleic acid |
US20020098513A1 (en) * | 2000-02-17 | 2002-07-25 | Glycominds Ltd. | Combinatorial complex carbohydrate libraries and methods for the manufacture and uses thereof |
US20040014102A1 (en) * | 2000-02-22 | 2004-01-22 | Shiping Chen | High density parallel printing of microarrays |
US6881538B1 (en) | 2000-03-05 | 2005-04-19 | 3M Innovative Properties Company | Array comprising diamond-like glass film |
US6649347B2 (en) | 2000-06-23 | 2003-11-18 | Chromatin, Inc. | Use of methylated nucleic acid segments for isolating centromere DNA |
US6890483B2 (en) * | 2000-07-05 | 2005-05-10 | Cuno Incorporated | Non-luminescent substrate |
WO2002002585A2 (en) * | 2000-07-05 | 2002-01-10 | Cuno, Inc. | Low fluorescence nylon/glass composites for microdiagnostics |
US20030219816A1 (en) * | 2001-07-02 | 2003-11-27 | Keith Solomon | Composite microarray slides |
AU2001273337B2 (en) | 2000-07-10 | 2006-06-29 | Board Of Regents, The University Of Texas System | Chromosome 3p21.3 genes are tumor suppressors |
US6913879B1 (en) * | 2000-07-10 | 2005-07-05 | Telechem International Inc. | Microarray method of genotyping multiple samples at multiple LOCI |
ATE399216T1 (en) * | 2000-07-11 | 2008-07-15 | Kirk Hogan | METHODS AND COMPOSITIONS FOR PERIOPERATIVE GENOMIC PROFILING |
US20020022231A1 (en) * | 2000-08-18 | 2002-02-21 | Vaughn Vasil | Method for identifying modulators of DNA structure-specific binding proteins by high-throughput screening |
AU2001286929A1 (en) * | 2000-09-01 | 2002-03-13 | Board Of Regents, The University Of Texas System | Compositions and methods for the generation of single stranded cdna microarrays with accurate universal quantitation reference |
TW523548B (en) * | 2000-09-04 | 2003-03-11 | Ind Tech Res Inst | High-density functional slide and preparation method thereof |
US6806051B2 (en) * | 2000-09-25 | 2004-10-19 | Picoliter Inc. | Arrays of partially nonhybridizing oligonucleotides and preparation thereof using focused acoustic energy |
US6962716B1 (en) * | 2000-09-27 | 2005-11-08 | Board Of Regents, The University Of Texas System | Compositions and methods for biodegradable microspheres as carriers of bioactive substances |
US7060442B2 (en) * | 2000-10-30 | 2006-06-13 | Regents Of The University Of Michigan | Modulators on Nod2 signaling |
US7205161B2 (en) * | 2001-01-10 | 2007-04-17 | Symyx Technologies, Inc. | Polymer brushes for immobilizing molecules to a surface or substrate having improved stability |
AU2002231934A1 (en) * | 2001-01-30 | 2002-08-12 | Solexa Ltd. | Arrayed polynucleotides and their use in genome analysis |
GB0119719D0 (en) * | 2001-08-13 | 2001-10-03 | Solexa Ltd | DNA sequence analysis |
US20060073530A1 (en) * | 2001-08-15 | 2006-04-06 | Olaf Schneewind | Methods and compositions involving sortase B |
US20030087309A1 (en) * | 2001-08-27 | 2003-05-08 | Shiping Chen | Desktop drug screening system |
US6916541B2 (en) | 2001-09-07 | 2005-07-12 | Penn State Research Foundation | Modified substrates for the attachment of biomolecules |
US7582425B2 (en) * | 2001-09-21 | 2009-09-01 | The Regents Of The University Of Michigan | Atlastin |
US7108975B2 (en) * | 2001-09-21 | 2006-09-19 | Regents Of The University Of Michigan | Atlastin |
US20040019005A1 (en) * | 2001-10-01 | 2004-01-29 | Jeffrey Van Ness | Methods for parallel measurement of genetic variations |
WO2003042697A1 (en) * | 2001-11-14 | 2003-05-22 | Genospectra, Inc. | Biochemical analysis system with combinatorial chemistry applications |
US20030148284A1 (en) * | 2001-12-17 | 2003-08-07 | Vision Todd J. | Solid phase detection of nucleic acid molecules |
AU2002359130A1 (en) * | 2001-12-21 | 2003-07-15 | Biacore Ab | Immobilization of binding agents |
US20070178477A1 (en) * | 2002-01-16 | 2007-08-02 | Nanomix, Inc. | Nanotube sensor devices for DNA detection |
US20060228723A1 (en) * | 2002-01-16 | 2006-10-12 | Keith Bradley | System and method for electronic sensing of biomolecules |
US7255986B2 (en) * | 2002-01-31 | 2007-08-14 | The Board Of Trustees Operating Michigan State University | Compositions for the diagnosis and treatment of epizootic catarrhal enteritis in ferrets |
US20070048180A1 (en) * | 2002-09-05 | 2007-03-01 | Gabriel Jean-Christophe P | Nanoelectronic breath analyzer and asthma monitor |
US7547931B2 (en) * | 2003-09-05 | 2009-06-16 | Nanomix, Inc. | Nanoelectronic capnometer adaptor including a nanoelectric sensor selectively sensitive to at least one gaseous constituent of exhaled breath |
US7522040B2 (en) * | 2004-04-20 | 2009-04-21 | Nanomix, Inc. | Remotely communicating, battery-powered nanostructure sensor devices |
HU226993B1 (en) * | 2002-03-29 | 2010-04-28 | Mta Szegedi Biolog Koezpont | Novel active carrier and process for immobilization of combinatorial compounds and compound libraries |
US7094537B2 (en) * | 2002-04-30 | 2006-08-22 | Agilent Technologies, Inc. | Micro arrays with structured and unstructured probes |
US7948041B2 (en) | 2005-05-19 | 2011-05-24 | Nanomix, Inc. | Sensor having a thin-film inhibition layer |
US7462448B2 (en) * | 2002-08-02 | 2008-12-09 | Stratatech Corporation | Species specific DNA detection |
KR101170653B1 (en) | 2002-08-12 | 2012-08-03 | 제네렉스, 인코포레이티드 | Methods and compositions concerning poxviruses and cancer |
AU2002951411A0 (en) * | 2002-09-16 | 2002-09-26 | The University Of Sydney | Genotype screen |
US20050009051A1 (en) * | 2002-09-27 | 2005-01-13 | Board Of Regents, The University Of Texas | Diagnosis of mould infection |
US20040067495A1 (en) * | 2002-10-08 | 2004-04-08 | Ray Gustav Allen | Polynucleic acid and polyamino acid binding substrate |
US6863731B2 (en) * | 2002-10-18 | 2005-03-08 | Controls Corporation Of America | System for deposition of inert barrier coating to increase corrosion resistance |
ATE525469T1 (en) | 2002-12-18 | 2011-10-15 | Third Wave Tech Inc | DETECTION OF SMALL NUCLEIC ACIDS |
US8206904B2 (en) | 2002-12-18 | 2012-06-26 | Third Wave Technologies, Inc. | Detection of nucleic acids |
US7297780B2 (en) | 2003-01-06 | 2007-11-20 | Third Wave Technologies, Inc. | Reactive functional groups for preparation of modified nucleic acid |
US20050037331A1 (en) * | 2003-08-13 | 2005-02-17 | William Galbraith | Apparatuses and methods for reducing albumin in samples |
US7964344B2 (en) * | 2003-09-17 | 2011-06-21 | Canon Kabushiki Kaisha | Stable hybrid |
WO2005029041A2 (en) * | 2003-09-19 | 2005-03-31 | Applera Corporation | High density sequence detection methods and apparatus |
US20050226771A1 (en) * | 2003-09-19 | 2005-10-13 | Lehto Dennis A | High speed microplate transfer |
US20050233472A1 (en) * | 2003-09-19 | 2005-10-20 | Kao H P | Spotting high density plate using a banded format |
US7972783B2 (en) * | 2003-11-24 | 2011-07-05 | Branhaven LLC | Method and markers for determining the genotype of horned/polled cattle |
US20050130177A1 (en) | 2003-12-12 | 2005-06-16 | 3M Innovative Properties Company | Variable valve apparatus and methods |
US7939249B2 (en) | 2003-12-24 | 2011-05-10 | 3M Innovative Properties Company | Methods for nucleic acid isolation and kits using a microfluidic device and concentration step |
US7727710B2 (en) * | 2003-12-24 | 2010-06-01 | 3M Innovative Properties Company | Materials, methods, and kits for reducing nonspecific binding of molecules to a surface |
US7432057B2 (en) * | 2004-01-30 | 2008-10-07 | Michigan State University | Genetic test for PSE-susceptible turkeys |
CA2557841A1 (en) * | 2004-02-27 | 2005-09-09 | President And Fellows Of Harvard College | Polony fluorescent in situ sequencing beads |
US7462451B2 (en) * | 2004-04-26 | 2008-12-09 | Third Wave Technologies, Inc. | Compositions for modifying nucleic acids |
US7026851B2 (en) * | 2004-05-12 | 2006-04-11 | System General Corp. | PWM controller having frequency jitter for power supplies |
EP2471921A1 (en) | 2004-05-28 | 2012-07-04 | Asuragen, Inc. | Methods and compositions involving microRNA |
EP1759009A1 (en) * | 2004-05-28 | 2007-03-07 | Board Of Regents, The University Of Texas System | Multigene predictors of response to chemotherapy |
EP1623996A1 (en) * | 2004-08-06 | 2006-02-08 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Improved method of selecting a desired protein from a library |
JP2008511008A (en) * | 2004-08-24 | 2008-04-10 | ナノミックス・インコーポレーテッド | Nanotube sensor device for DNA detection |
ES2345993T3 (en) | 2004-09-14 | 2010-10-07 | The Regents Of The University Of Colorado, A Body Corporate | METHOD FOR TREATMENT WITH BUCINDOLOL BASED ON GENETIC ADDRESSING. |
EP2302054B1 (en) | 2004-11-12 | 2014-07-16 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
WO2006124664A2 (en) * | 2005-05-12 | 2006-11-23 | Third Wave Technologies, Inc. | Polymorphic ghsr nucleic acids and uses thereof |
AU2006248189A1 (en) | 2005-05-20 | 2006-11-23 | Synergenz Bioscience Limited | Methods of analysis of polymorphisms and uses thereof |
SG162795A1 (en) | 2005-06-15 | 2010-07-29 | Callida Genomics Inc | Single molecule arrays for genetic and chemical analysis |
US8980246B2 (en) | 2005-09-07 | 2015-03-17 | Sillajen Biotherapeutics, Inc. | Oncolytic vaccinia virus cancer therapy |
CA2621982C (en) * | 2005-09-07 | 2017-11-28 | Jennerex Biotherapeutics Ulc | Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses |
US20070141723A1 (en) * | 2005-12-16 | 2007-06-21 | Sompuram Seshi A | Immunohistochemistry staining controls |
DE602006013511D1 (en) * | 2005-12-29 | 2010-05-20 | Ind Cooperation Agency | ONE STEP DIAGNOSIS WITH DNA CHIP |
JP2009522576A (en) * | 2006-01-03 | 2009-06-11 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Small molecule printing |
CA2653671A1 (en) * | 2006-05-30 | 2007-12-06 | Synergenz Bioscience Limited | Methods and compositions for assessment of pulmonary function and disorders |
JP5260503B2 (en) | 2006-06-01 | 2013-08-14 | サード ウェーブ テクノロジーズ,インコーポレーテッド | Nucleic acid detection |
WO2007141811A2 (en) * | 2006-06-06 | 2007-12-13 | Stmicroelectronics S.R.L. | Process for preparing a semiconductor substrate for biological analysis |
US7759062B2 (en) * | 2006-06-09 | 2010-07-20 | Third Wave Technologies, Inc. | T-structure invasive cleavage assays, consistent nucleic acid dispensing, and low level target nucleic acid detection |
HUP0600668A2 (en) | 2006-08-22 | 2008-02-28 | Avicor Kft | Active carrier, process for producing thereof and the use of thereof |
US8481023B2 (en) | 2006-09-15 | 2013-07-09 | Ottawa Hospital Research Institute | Oncolytic rhabdovirus |
WO2008036765A2 (en) | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | Micrornas differentially expressed in pancreatic diseases and uses thereof |
CA2663962A1 (en) | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | Mir-15, mir-26, mir-31,mir-145, mir-147, mir-188, mir-215, mir-216, mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention |
US20080081330A1 (en) * | 2006-09-28 | 2008-04-03 | Helicos Biosciences Corporation | Method and devices for analyzing small RNA molecules |
CA2666584A1 (en) * | 2006-10-17 | 2008-04-24 | Synergenz Bioscience Limited | Methods and compositions for assessment of pulmonary function and disorders |
WO2008075977A2 (en) * | 2006-12-19 | 2008-06-26 | Synergenz Bioscience Limited | Methods and compositions for the assessment of cardiovascular function and disorders |
GB0702092D0 (en) * | 2007-02-02 | 2007-03-14 | Fracture Code Corp Aps | Graphic Code Application Apparatus and Method |
AU2008331824B2 (en) | 2007-12-04 | 2014-07-24 | Pacific Biosciences Of California, Inc. | Alternate labeling strategies for single molecule sequencing |
US20110045481A1 (en) | 2008-01-25 | 2011-02-24 | Patrick Gladding | Methods and compositions for the assessment of drug response |
US20090215050A1 (en) * | 2008-02-22 | 2009-08-27 | Robert Delmar Jenison | Systems and methods for point-of-care amplification and detection of polynucleotides |
EP2257646A1 (en) * | 2008-02-29 | 2010-12-08 | ISIS Innovation Limited | Diagnostic methods |
US20090253142A1 (en) * | 2008-03-15 | 2009-10-08 | Hologic, Inc. | Compositions and methods for analysis of nucleic acid molecules during amplification reactions |
EP2286217B1 (en) | 2008-03-31 | 2015-02-18 | Pacific Biosciences of California, Inc. | Single molecule loading methods and compositions |
WO2009137369A1 (en) * | 2008-05-03 | 2009-11-12 | Tufts Medical Center, Inc. | Neonatal salivary genomics |
WO2009137807A2 (en) | 2008-05-08 | 2009-11-12 | Asuragen, Inc. | Compositions and methods related to mirna modulation of neovascularization or angiogenesis |
GB0808350D0 (en) * | 2008-05-09 | 2008-06-18 | Airbus Uk Ltd | Self-cleaning surfaces |
US9817001B2 (en) | 2008-05-27 | 2017-11-14 | Boston Heart Diagnostics Corporation | Methods for determining LDL cholesterol treatment |
US8470541B1 (en) | 2008-09-27 | 2013-06-25 | Boston Heart Diagnostics Corporation | Methods for separation and immuno-detection of biomolecules, and apparatus related thereto |
US9409983B2 (en) | 2009-07-23 | 2016-08-09 | The Board Of Trustess Of The University Of Illinois | Methods and compositions involving PBEF inhibitors for lung inflammation conditions and diseases |
US9512481B2 (en) | 2009-09-11 | 2016-12-06 | The Regents Of The University Of Colorado, A Body Corporate | Polymorphisms in the PDE3A gene |
KR101838472B1 (en) | 2009-09-14 | 2018-03-15 | 신라젠(주) | Oncolytic vaccinia virus combination cancer therapy |
WO2011048498A2 (en) | 2009-10-19 | 2011-04-28 | Stichting Het Nederlands Kanker Instituut | Differentiation between brca2-associated tumours and sporadic tumours via array comparative genomic hybridization |
US20120277112A1 (en) | 2009-10-19 | 2012-11-01 | Stichting Het Nederlands Kanker Instituut | Predicting response to anti-cancer therapy via array comparative genomic hybridization |
WO2011048495A1 (en) | 2009-10-19 | 2011-04-28 | Stichting Het Nederlands Kanker Instituut | Predicting benefit of anti-cancer therapy via array comparative genomic hybridization |
WO2011059453A1 (en) * | 2009-11-16 | 2011-05-19 | Postech Academy-Industry Foundation | Methods for producing surface bound oligonucleotide on solid substrate and uses thereof |
MX365946B (en) | 2009-12-10 | 2019-06-19 | Turnstone Lp | Oncolytic rhabdovirus. |
EP2515899B1 (en) | 2009-12-23 | 2016-05-25 | ARCA biopharma, Inc. | Methods and compositions for cardiovascular diseases and conditions |
WO2011108930A1 (en) | 2010-03-04 | 2011-09-09 | Interna Technologies Bv | A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS DIAGNOSTIC AND THERAPEUTIC USES IN DISEASES OR CONDITIONS ASSOCIATED WITH EMT |
JP5893607B2 (en) | 2010-04-05 | 2016-03-23 | プログノシス バイオサイエンシズ インコーポレイテッドPrognosys Biosciences,Inc. | Spatial-encoded biological assay |
US10787701B2 (en) | 2010-04-05 | 2020-09-29 | Prognosys Biosciences, Inc. | Spatially encoded biological assays |
US20190300945A1 (en) | 2010-04-05 | 2019-10-03 | Prognosys Biosciences, Inc. | Spatially Encoded Biological Assays |
WO2011139344A2 (en) | 2010-04-28 | 2011-11-10 | Pacific Biosciences Of California, Inc | Nanoscale apertures having islands of functionality |
NZ719520A (en) | 2010-07-06 | 2017-07-28 | Int Tech Bv | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway |
US20140018251A1 (en) | 2010-09-20 | 2014-01-16 | Stichting Het Nederlands Kanker Instituut | Methods for Predicting Response to Anti-Cancer Therapy in Cancer Patients |
ES2629890T3 (en) | 2010-11-17 | 2017-08-16 | Interpace Diagnostics, Llc | miRNA as biomarkers to distinguish between benign and malignant thyroid neoplasms |
JP6121910B2 (en) | 2011-01-04 | 2017-04-26 | シラジェン バイオセラピューティクス インコーポレイテッド | Generation of antibodies against tumor antigens and tumor-specific complement-dependent cytotoxicity by administration of oncolytic vaccinia virus |
EP2474617A1 (en) | 2011-01-11 | 2012-07-11 | InteRNA Technologies BV | Mir for treating neo-angiogenesis |
WO2012158238A2 (en) | 2011-02-28 | 2012-11-22 | University Of Iowa Research Foundation | Anti-müllerian hormone changes in pregnancy and prediction ofadverse pregnancy outcomes and gender |
EP2683835B1 (en) | 2011-03-08 | 2017-01-11 | King Abdullah University Of Science And Technology | Molecular biomarker set for early detection of ovarian cancer |
GB201106254D0 (en) | 2011-04-13 | 2011-05-25 | Frisen Jonas | Method and product |
US9364532B2 (en) | 2011-06-08 | 2016-06-14 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Compositions and methods for glioblastoma treatment |
WO2013036799A2 (en) | 2011-09-09 | 2013-03-14 | Fred Hutchinson Cancer Research Center | Methods and compositions involving nkg2d inhibitors and cancer |
WO2013040251A2 (en) | 2011-09-13 | 2013-03-21 | Asurgen, Inc. | Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease |
CA2851838A1 (en) | 2011-10-13 | 2013-04-18 | Boston Heart Diagnostics Corporation | Compositions and methods for treating and preventing coronary heart disease |
WO2013063519A1 (en) | 2011-10-26 | 2013-05-02 | Asuragen, Inc. | Methods and compositions involving mirna expression levels for distinguishing pancreatic cysts |
US20130142728A1 (en) | 2011-10-27 | 2013-06-06 | Asuragen, Inc. | Mirnas as diagnostic biomarkers to distinguish benign from malignant thyroid tumors |
WO2013087789A1 (en) | 2011-12-13 | 2013-06-20 | Glykos Finland Ltd. | Antibody isoform arrays and methods thereof |
EP2836482B1 (en) | 2012-04-10 | 2019-12-25 | The Regents of The University of California | Compositions and methods for treating cancer |
EP2870263A1 (en) | 2012-07-03 | 2015-05-13 | InteRNA Technologies B.V. | Diagnostic portfolio and its uses |
US20140100124A1 (en) | 2012-10-04 | 2014-04-10 | Asuragen, Inc. | Diagnostic mirnas for differential diagnosis of incidental pancreatic cystic lesions |
WO2014116721A1 (en) | 2013-01-22 | 2014-07-31 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Geminiviral vector for expression of rituximab |
RU2684211C2 (en) | 2013-02-21 | 2019-04-04 | Тёрнстоун Лимитед Партнершип | Vaccine composition |
US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
EP2970909A4 (en) | 2013-03-15 | 2017-02-15 | The University of Chicago | Methods and compositions related to t-cell activity |
WO2014151551A1 (en) | 2013-03-15 | 2014-09-25 | Baylor Research Institute | Ulcerative colitis (uc)-associated colorectal neoplasia markers |
EP2971132B1 (en) | 2013-03-15 | 2020-05-06 | Baylor Research Institute | Tissue and blood-based mirna biomarkers for the diagnosis, prognosis and metastasis-predictive potential in colorectal cancer |
WO2014210225A1 (en) | 2013-06-25 | 2014-12-31 | Prognosys Biosciences, Inc. | Methods and systems for determining spatial patterns of biological targets in a sample |
US9828624B2 (en) | 2013-07-24 | 2017-11-28 | Boston Heart Diagnostics Corporation | Driving patient compliance with therapy |
JO3805B1 (en) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | Inhibitors of kras g12c |
JO3556B1 (en) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | Combination therapies for treatment of cancer |
WO2016049524A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
EP3220810A4 (en) | 2014-11-17 | 2018-05-16 | Boston Heart Diagnostic Corporation | Cardiovascular disease risk assessment |
WO2016086227A2 (en) | 2014-11-26 | 2016-06-02 | The Regents Of The University Of California | Therapeutic compositions comprising transcription factors and methods of making and using the same |
US10774374B2 (en) | 2015-04-10 | 2020-09-15 | Spatial Transcriptomics AB and Illumina, Inc. | Spatially distinguished, multiplex nucleic acid analysis of biological specimens |
BR112017021869A2 (en) | 2015-04-10 | 2018-12-11 | Araxes Pharma Llc | substituted quinazoline compounds and methods of use thereof |
MX2017013275A (en) | 2015-04-15 | 2018-01-26 | Araxes Pharma Llc | Fused-tricyclic inhibitors of kras and methods of use thereof. |
US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
WO2017058792A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
WO2017058807A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
US10647703B2 (en) | 2015-09-28 | 2020-05-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
EP3356354A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
WO2017058728A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
US10689356B2 (en) | 2015-09-28 | 2020-06-23 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
EP3356349A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
JP2018533939A (en) | 2015-10-19 | 2018-11-22 | アラクセス ファーマ エルエルシー | Method for screening for inhibitors of RAS |
KR20180081596A (en) | 2015-11-16 | 2018-07-16 | 아락세스 파마 엘엘씨 | Substituted quinazoline compounds comprising substituted heterocyclic groups and methods for their use |
US9988357B2 (en) | 2015-12-09 | 2018-06-05 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
US10280172B2 (en) | 2016-09-29 | 2019-05-07 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
CN110312711A (en) | 2016-10-07 | 2019-10-08 | 亚瑞克西斯制药公司 | Heterocyclic compound and its application method as RAS inhibitor |
WO2018112420A1 (en) | 2016-12-15 | 2018-06-21 | The Regents Of The University Of California | Compositions and methods for treating cancer |
WO2018140599A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
EP3573971A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
EP3573954A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
EP3573967A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused hetero-hetero bicyclic compounds and methods of use thereof |
WO2018140514A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
WO2018218069A1 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant kras, hras or nras |
CN110869357A (en) | 2017-05-25 | 2020-03-06 | 亚瑞克西斯制药公司 | Compounds and methods of use thereof for treating cancer |
WO2018218070A2 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Covalent inhibitors of kras |
US11497762B2 (en) | 2017-11-03 | 2022-11-15 | Interna Technologies B.V. | MiRNA molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation |
EP3844308A1 (en) | 2018-08-28 | 2021-07-07 | 10X Genomics, Inc. | Resolving spatial arrays |
US20230323447A1 (en) | 2018-08-28 | 2023-10-12 | 10X Genomics, Inc. | Method for transposase-mediated spatial tagging and analyzing genomic dna in a biological sample |
US11519033B2 (en) | 2018-08-28 | 2022-12-06 | 10X Genomics, Inc. | Method for transposase-mediated spatial tagging and analyzing genomic DNA in a biological sample |
CN111100786B (en) * | 2018-10-25 | 2022-03-25 | 深圳市真迈生物科技有限公司 | Solid phase substrate, method for treating same and use thereof |
JP2022509018A (en) | 2018-10-31 | 2022-01-20 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ | Biomarkers and usage for radiation-induced lung injury |
WO2020123316A2 (en) | 2018-12-10 | 2020-06-18 | 10X Genomics, Inc. | Methods for determining a location of a biological analyte in a biological sample |
US11358137B2 (en) | 2018-12-26 | 2022-06-14 | Industrial Technology Research Institute | Tubular structure for producing droplets and method for producing droplets |
US11926867B2 (en) | 2019-01-06 | 2024-03-12 | 10X Genomics, Inc. | Generating capture probes for spatial analysis |
US11649485B2 (en) | 2019-01-06 | 2023-05-16 | 10X Genomics, Inc. | Generating capture probes for spatial analysis |
CN114174531A (en) | 2019-02-28 | 2022-03-11 | 10X基因组学有限公司 | Profiling of biological analytes with spatially barcoded oligonucleotide arrays |
WO2020190509A1 (en) | 2019-03-15 | 2020-09-24 | 10X Genomics, Inc. | Methods for using spatial arrays for single cell sequencing |
WO2020198071A1 (en) | 2019-03-22 | 2020-10-01 | 10X Genomics, Inc. | Three-dimensional spatial analysis |
KR20210151944A (en) | 2019-04-12 | 2021-12-14 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | Compositions and methods for increasing muscle mass and oxidative metabolism |
EP3976820A1 (en) | 2019-05-30 | 2022-04-06 | 10X Genomics, Inc. | Methods of detecting spatial heterogeneity of a biological sample |
EP4055185A1 (en) | 2019-11-08 | 2022-09-14 | 10X Genomics, Inc. | Spatially-tagged analyte capture agents for analyte multiplexing |
AU2020388047A1 (en) | 2019-11-18 | 2022-06-23 | 10X Genomics, Inc. | Systems and methods for tissue classification |
CN117078725A (en) | 2019-11-21 | 2023-11-17 | 10X基因组学有限公司 | Spatial analysis of analytes |
WO2021102005A1 (en) | 2019-11-22 | 2021-05-27 | 10X Genomics, Inc. | Systems and methods for spatial analysis of analytes using fiducial alignment |
US11821035B1 (en) | 2020-01-29 | 2023-11-21 | 10X Genomics, Inc. | Compositions and methods of making gene expression libraries |
JP2023514749A (en) | 2020-02-21 | 2023-04-07 | 10エックス ジェノミクス インコーポレイテッド | Methods and compositions for integrated in situ spatial assays |
KR20230169143A (en) | 2021-03-11 | 2023-12-15 | 노틸러스 서브시디어리, 인크. | Systems and methods for retaining biomolecules |
WO2023215603A1 (en) | 2022-05-06 | 2023-11-09 | 10X Genomics, Inc. | Methods and compositions for in situ analysis of v(d)j sequences |
WO2024028794A1 (en) | 2022-08-02 | 2024-02-08 | Temple Therapeutics BV | Methods for treating endometrial and ovarian hyperproliferative disorders |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4521509A (en) * | 1982-11-24 | 1985-06-04 | Research Corporation | Method for degrading DNA |
GB8311018D0 (en) * | 1983-04-22 | 1983-05-25 | Amersham Int Plc | Detecting mutations in dna |
GB8606719D0 (en) * | 1986-03-19 | 1986-04-23 | Lister Preventive Med | Genetic probes |
KR920700360A (en) * | 1989-03-22 | 1992-02-19 | 하리크 프리드리히 | Sliding bearing |
US5075217A (en) * | 1989-04-21 | 1991-12-24 | Marshfield Clinic | Length polymorphisms in (dC-dA)n ·(dG-dT)n sequences |
WO1990013668A1 (en) * | 1989-05-05 | 1990-11-15 | Lifecodes Corporation | Method for genetic analysis of a nucleic acid sample |
FR2650840B1 (en) * | 1989-08-11 | 1991-11-29 | Bertin & Cie | RAPID DETECTION AND / OR IDENTIFICATION OF A SINGLE BASED ON A NUCLEIC ACID SEQUENCE, AND ITS APPLICATIONS |
US5302509A (en) * | 1989-08-14 | 1994-04-12 | Beckman Instruments, Inc. | Method for sequencing polynucleotides |
WO1991014003A2 (en) * | 1990-03-09 | 1991-09-19 | Ig Laboratories, Inc. | Characterization and analysis of polymorphic vntr loci |
US6004744A (en) * | 1991-03-05 | 1999-12-21 | Molecular Tool, Inc. | Method for determining nucleotide identity through extension of immobilized primer |
US5518900A (en) * | 1993-01-15 | 1996-05-21 | Molecular Tool, Inc. | Method for generating single-stranded DNA molecules |
IL108159A (en) * | 1993-12-23 | 1998-02-08 | Orgenics Ltd | Apparatus for separation, concentration and detection of target molecules in liquid sample |
DE19518217A1 (en) * | 1994-05-11 | 1995-11-30 | Imtec Immundiagnostika Gmbh | Determn of DNA after capture by probe immobilised on solid phase |
-
1997
- 1997-06-06 US US08/870,010 patent/US5919626A/en not_active Expired - Lifetime
-
1998
- 1998-06-05 JP JP50294099A patent/JP2002506347A/en active Pending
- 1998-06-05 AU AU77260/98A patent/AU739412B2/en not_active Expired
- 1998-06-05 WO PCT/US1998/011662 patent/WO1998055593A1/en not_active Application Discontinuation
- 1998-06-05 EP EP98925267A patent/EP0996705A4/en not_active Ceased
- 1998-06-05 CA CA002292896A patent/CA2292896A1/en not_active Abandoned
- 1998-06-23 US US09/102,371 patent/US6136962A/en not_active Expired - Lifetime
-
2000
- 2000-08-14 US US09/638,436 patent/US6387626B1/en not_active Expired - Fee Related
Non-Patent Citations (6)
Title |
---|
BEATTIE K. L., ET AL.: "ADVANCES IN GENOSENSOR RESEARCH.", CLINICAL CHEMISTRY., AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY, WASHINGTON, DC., vol. 41., no. 05., 1 January 1995 (1995-01-01), WASHINGTON, DC., pages 700 - 706., XP002912131, ISSN: 0009-9147 * |
BLANCHARD A. P., KAISER R. J., HOOD L. E.: "HIGH-DENSITY OLIGONUCLEOTIDE ARRAYS.", BIOSENSORS AND BIOELECTRONICS, ELSEVIER BV, NL, vol. 11., no. 06/07., 1 June 1996 (1996-06-01), NL, pages 687 - 690., XP002912127, ISSN: 0956-5663, DOI: 10.1016/0956-5663(96)83302-1 * |
MASKOS U., SOUTHERN E. M.: "OLIGONUCLEOTIDE HYBRIDISATIONS ON GLASS SUPPORTS: A NOVEL LINKER FOR OLIGONUCLEOTIDE SYNTHESIS AND HYBRIDISATION PROPERTIES OF OLIGONUCLEOTIDES SYNTHESISED IN SITU.", NUCLEIC ACIDS RESEARCH, INFORMATION RETRIEVAL LTD., GB, vol. 20., no. 07., 11 April 1992 (1992-04-11), GB, pages 1679 - 1684., XP002912129, ISSN: 0305-1048 * |
See also references of EP0996705A4 * |
SOUTHERN E. M.: "DETECTION OF SPECIFIC SEQUENCES AMONG DNA FRAGMENTS SEPARATED BY GEL ELECTROPHORESIS.", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 98., 15 October 1975 (1975-10-15), United Kingdom, pages 503 - 517., XP002912128, ISSN: 0022-2836, DOI: 10.1016/S0022-2836(75)80083-0 * |
STIMPSON D. I., ET AL.: "REAL-TIME DETECTION OF DNA HYBRIDIZATION AND MELTING ON OLIGONUCLEOTIDE ARRAYS BY USING OPTICAL WAVE GUIDES.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 92., 1 July 1995 (1995-07-01), US, pages 6379 - 6383., XP002912130, ISSN: 0027-8424, DOI: 10.1073/pnas.92.14.6379 * |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7645596B2 (en) | 1998-05-01 | 2010-01-12 | Arizona Board Of Regents | Method of determining the nucleotide sequence of oligonucleotides and DNA molecules |
US10214774B2 (en) | 1998-05-01 | 2019-02-26 | Life Technologies Corporation | Method of determining the nucleotide sequence of oligonucleotides and DNA molecules |
US10208341B2 (en) | 1998-05-01 | 2019-02-19 | Life Technologies Corporation | Method of determining the nucleotide sequence of oligonucleotides and DNA molecules |
US9957561B2 (en) | 1998-05-01 | 2018-05-01 | Life Technologies Corporation | Method of determining the nucleotide sequence of oligonucleotides and DNA molecules |
US9725764B2 (en) | 1998-05-01 | 2017-08-08 | Life Technologies Corporation | Method of determining the nucleotide sequence of oligonucleotides and DNA molecules |
US9540689B2 (en) | 1998-05-01 | 2017-01-10 | Life Technologies Corporation | Method of determining the nucleotide sequence of oligonucleotides and DNA molecules |
US9458500B2 (en) | 1998-05-01 | 2016-10-04 | Life Technologies Corporation | Method of determining the nucleotide sequence of oligonucleotides and DNA molecules |
US9212393B2 (en) | 1998-05-01 | 2015-12-15 | Life Technologies Corporation | Method of determining the nucleotide sequence of oligonucleotides and DNA molecules |
US9096898B2 (en) | 1998-05-01 | 2015-08-04 | Life Technologies Corporation | Method of determining the nucleotide sequence of oligonucleotides and DNA molecules |
US7501245B2 (en) | 1999-06-28 | 2009-03-10 | Helicos Biosciences Corp. | Methods and apparatuses for analyzing polynucleotide sequences |
EP1104687A2 (en) * | 1999-11-29 | 2001-06-06 | Nisshinbo Industries, Inc. | Nucleic acid-immobilized substrate |
EP1104687A3 (en) * | 1999-11-29 | 2001-11-21 | Nisshinbo Industries, Inc. | Nucleic acid-immobilized substrate |
US6498245B2 (en) | 1999-11-29 | 2002-12-24 | Nisshinbo Industries, Inc. | Nucleic acid-immobilized substrate |
WO2001062378A3 (en) * | 2000-02-22 | 2002-02-07 | Genospectra Inc | Microarray fabrication techniques and apparatus |
US6953551B2 (en) | 2000-02-22 | 2005-10-11 | Genospectra, Inc. | Microarray fabrication techniques and apparatus |
US6594432B2 (en) | 2000-02-22 | 2003-07-15 | Genospectra, Inc. | Microarray fabrication techniques and apparatus |
WO2001062378A2 (en) * | 2000-02-22 | 2001-08-30 | Genospectra, Inc. | Microarray fabrication techniques and apparatus |
WO2001062377A2 (en) * | 2000-02-22 | 2001-08-30 | Genospectra, Inc. | Microarray fabrication techniques and apparatus |
WO2001062377A3 (en) * | 2000-02-22 | 2002-03-14 | Genospectra Inc | Microarray fabrication techniques and apparatus |
DE10029914A1 (en) * | 2000-06-19 | 2002-01-03 | Epigenomics Ag | Method for the highly parallel analysis of polymorphisms |
EP1223149A1 (en) * | 2001-01-10 | 2002-07-17 | Corning Incorporated | Silsesquioxane-coated substrates for immobilizing biomolecules |
JP2005519634A (en) * | 2001-10-12 | 2005-07-07 | スペクトラル ジェノミクス、インク. | Nucleic acid compositions and arrays and methods using them |
US9657344B2 (en) | 2003-11-12 | 2017-05-23 | Fluidigm Corporation | Short cycle methods for sequencing polynucleotides |
US9012144B2 (en) | 2003-11-12 | 2015-04-21 | Fluidigm Corporation | Short cycle methods for sequencing polynucleotides |
US7981604B2 (en) | 2004-02-19 | 2011-07-19 | California Institute Of Technology | Methods and kits for analyzing polynucleotide sequences |
US9868978B2 (en) | 2005-08-26 | 2018-01-16 | Fluidigm Corporation | Single molecule sequencing of captured nucleic acids |
US7666593B2 (en) | 2005-08-26 | 2010-02-23 | Helicos Biosciences Corporation | Single molecule sequencing of captured nucleic acids |
Also Published As
Publication number | Publication date |
---|---|
US5919626A (en) | 1999-07-06 |
CA2292896A1 (en) | 1998-12-10 |
US6387626B1 (en) | 2002-05-14 |
AU7726098A (en) | 1998-12-21 |
AU739412B2 (en) | 2001-10-11 |
JP2002506347A (en) | 2002-02-26 |
EP0996705A1 (en) | 2000-05-03 |
US6136962A (en) | 2000-10-24 |
EP0996705A4 (en) | 2004-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU739412B2 (en) | Attachment of unmodified nucleic acids to silanized solid phase surfaces | |
AU739010B2 (en) | Covalent attachment of nucleic acid molecules onto solid-phases via disulfide bonds | |
US5610287A (en) | Method for immobilizing nucleic acid molecules | |
US6248521B1 (en) | Amplification and other enzymatic reactions performed on nucleic acid arrays | |
AU752579C (en) | De Novo or "universal" sequencing array | |
AU742599B2 (en) | Multiple functionalities within an array element and uses thereof | |
JP2002518024A (en) | Polymerase signal formation assay |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2292896 Country of ref document: CA Ref country code: CA Ref document number: 2292896 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 77260/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998925267 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1998925267 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 77260/98 Country of ref document: AU |
|
WWR | Wipo information: refused in national office |
Ref document number: 1998925267 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998925267 Country of ref document: EP |